Does a broad serum neural-antibody pattern prove autoimmune neurologic disease?

Serum neural-antibody panels are most informative when interpreted as part of a syndrome-based evaluation, not as standalone evidence of autoimmune neurologic disease. This is particularly relevant when a panel yields several low-level or unexpected positive results.

Interpretation of broad serum reactivity

• A broad multi-antibody serum pattern does not by itself establish true immune reactivity to multiple neural targets. In a retrospective series, 11 of 63 antibody-positive samples had more than one positive result, while 39 of 63 total results were judged nonspecific, often in people with alternative diagnoses.
• Genuine coexistence of neural antibodies can occur: 22 of 276 antibody-positive autoimmune-encephalitis patients in one cohort had multiple antibodies. However, a broad serum pattern alone cannot distinguish true coexisting target-specific antibodies from nonspecific binding or assay-related false positivity.
• Unexpected, weak, or serum-only findings should therefore prompt verification rather than diagnostic attribution.

Clinical and laboratory determinants of significance

• Antibody identity matters. CSF testing is particularly important for NMDAR antibodies, whereas serum can be more sensitive for LGI1 antibodies; a serum-only positive result therefore has different implications depending on the target.
• Assay validity matters. Antibody-appropriate validated methods and an orthogonal confirmation method are important for atypical or discordant findings, especially because standalone commercial line blots can produce false-positive intracellular/onconeural-antibody results.
• Titer is contextual. Low-level serum reactivity, notably GAD65 in an incompatible syndrome, may be incidental; higher GAD65 levels are more supportive when paired with a characteristic neurologic phenotype. No universal titer cutoff applies across assays or antibodies.
• Phenotype and objective CNS evidence are essential. A compatible subacute neurologic syndrome, MRI abnormalities consistent with encephalitis, CSF inflammation, and relevant EEG changes strengthen attribution. Paired serum–CSF testing can resolve clinically dubious serum-only results.

Bottom line

• A broad serum neural-antibody pattern is a reason for careful antibody-specific confirmation and clinical correlation—not proof of multiple pathogenic neural immune responses.